GIOTRIF (Afatinib)
Targeted Therapy for EGFR Mutation-Positive Non-Small Cell Lung Cancer
Quick Facts About GIOTRIF
Key Takeaways About GIOTRIF (Afatinib)
- Targeted EGFR therapy: GIOTRIF irreversibly blocks the ErbB family of receptors (EGFR, HER2, ErbB3, ErbB4), providing sustained inhibition of cancer cell growth in EGFR mutation-positive NSCLC
- First-line or second-line treatment: Approved for first-line use in EGFR mutation-positive NSCLC and for squamous NSCLC after prior platinum-based chemotherapy
- Diarrhoea management is critical: Diarrhoea occurs in over 90% of patients — have anti-diarrhoeal medication ready before starting treatment and begin it at the first sign of symptoms
- Take on an empty stomach: Must be taken at least 1 hour before or 3 hours after food to ensure proper absorption
- Dose adjustments may be needed: Your doctor may increase or decrease the dose based on how well you tolerate the medication and the severity of side effects
What Is GIOTRIF and What Is It Used For?
Quick Answer: GIOTRIF (afatinib) is a targeted oral cancer medicine that works by irreversibly blocking a group of proteins called the ErbB family, which drive the growth and spread of certain types of lung cancer. It is prescribed for adults with non-small cell lung cancer (NSCLC) that is driven by specific genetic mutations.
GIOTRIF contains the active substance afatinib, which belongs to a class of cancer medicines known as tyrosine kinase inhibitors (TKIs). Unlike some other targeted therapies that reversibly bind to their target, afatinib forms a permanent (irreversible) bond with the ErbB family of proteins. This family includes the epidermal growth factor receptor (EGFR, also called ErbB1), HER2 (ErbB2), ErbB3, and ErbB4. These proteins play a crucial role in signalling pathways that regulate cell growth, division, and survival. When mutations occur in the genes that encode these proteins — particularly EGFR — the signalling can become overactive, leading to uncontrolled cancer cell proliferation.
By covalently binding to and permanently blocking these receptors, GIOTRIF shuts down the downstream signalling cascades (including the RAS/RAF/MEK/ERK and PI3K/AKT pathways) that cancer cells rely on to grow and spread. This targeted approach means the drug acts primarily on cancer cells with these specific molecular alterations, although it can also affect normal cells that express these proteins, which accounts for many of its side effects.
GIOTRIF is approved for two main indications in adults:
- EGFR mutation-positive NSCLC: For patients whose tumour has been identified as having activating mutations in the EGFR gene (such as exon 19 deletions or exon 21 L858R point mutations). GIOTRIF can be prescribed as the first cancer treatment (first-line therapy) or if prior chemotherapy has been inadequate.
- Squamous NSCLC: For patients with squamous cell carcinoma of the lung whose cancer has progressed during or after platinum-based chemotherapy. In this setting, GIOTRIF is used regardless of EGFR mutation status.
Non-small cell lung cancer accounts for approximately 80–85% of all lung cancers worldwide. EGFR mutations are found in roughly 10–15% of NSCLC patients in Western populations and up to 40–50% in East Asian populations. The identification of EGFR mutations through molecular testing of tumour tissue has transformed the treatment landscape, enabling targeted therapies like GIOTRIF to provide improved outcomes compared with traditional chemotherapy in appropriately selected patients.
What Should You Know Before Taking GIOTRIF?
Quick Answer: Do not take GIOTRIF if you are allergic to afatinib or any of its excipients. Before starting treatment, inform your doctor about any pre-existing lung disease, liver or kidney problems, eye conditions, or heart disease, as these may require closer monitoring or make GIOTRIF unsuitable for you.
Contraindications
GIOTRIF must not be taken if you have a known hypersensitivity (allergy) to afatinib or any of the other ingredients in the tablet, including lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, hypromellose, macrogol 400, titanium dioxide, talc, and polysorbat 80. Allergic reactions can range from mild skin reactions to severe anaphylaxis. If you experience any signs of a severe allergic reaction — such as difficulty breathing, swelling of the face or throat, or a widespread rash — seek emergency medical attention immediately.
Warnings and Precautions
Before starting GIOTRIF, speak with your doctor or pharmacist if any of the following conditions apply to you, as they may influence how you are monitored during treatment:
- Female sex, low body weight (<50 kg), or kidney problems: These factors are associated with higher blood levels of afatinib, which may increase the severity of side effects. Your doctor may monitor you more closely and may start you on a lower dose.
- History of interstitial lung disease (ILD): Previous inflammation of the lung tissue is a serious concern. ILD can occur during GIOTRIF treatment and can be life-threatening. If you experience new or worsening breathlessness, potentially with cough and fever, contact your doctor immediately.
- Liver problems: Your doctor should perform liver function tests before and during treatment. GIOTRIF is not recommended for patients with severe hepatic impairment.
- Eye problems: If you have a history of severe dry eyes, corneal inflammation (keratitis), corneal ulcers, or use contact lenses, inform your doctor. GIOTRIF can cause or worsen eye problems.
- Heart problems: Patients with a history of cardiac conditions may need closer monitoring during treatment, including assessment of left ventricular ejection fraction.
- New or worsening breathlessness, with or without cough and fever (possible interstitial lung disease)
- Severe stomach or abdominal pain, fever, chills, nausea, vomiting, or a rigid/bloated abdomen (possible gastrointestinal perforation)
- Severe diarrhoea lasting more than 2 days despite anti-diarrhoeal treatment
- Severe skin reactions with blistering and peeling
- Acute eye redness, pain, increased tearing, blurred vision, or light sensitivity
Additionally, if you have a history of gastrointestinal ulcers, diverticular disease, or are taking non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids concurrently, your risk of gastrointestinal perforation may be increased. Discuss this with your doctor before starting treatment.
Pregnancy and Breastfeeding
GIOTRIF should be avoided during pregnancy as it may cause harm to the developing baby. Animal studies have shown adverse effects on foetal development. If you are of childbearing potential, you must use reliable contraception during treatment and for at least 1 month after your last dose. If you become pregnant while taking GIOTRIF, inform your doctor immediately so that together you can decide whether to continue treatment.
Breastfeeding is not recommended during GIOTRIF treatment, as the risk to the nursing infant cannot be excluded. The decision on whether to discontinue breastfeeding or to discontinue GIOTRIF should take into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
If you are planning to become pregnant after completing treatment, consult your doctor, as afatinib may still be present in your body for some time after the last dose.
Driving and Operating Machinery
If you experience treatment-related symptoms that affect your vision (such as eye redness, irritation, dry eyes, or increased tearing) or your ability to concentrate and react, you should avoid driving or operating machinery until the symptoms have resolved.
How Does GIOTRIF Interact with Other Drugs?
Quick Answer: GIOTRIF is primarily transported by P-glycoprotein (P-gp). Drugs that inhibit P-gp (such as ritonavir, ketoconazole, and verapamil) can increase GIOTRIF blood levels, while P-gp inducers (such as rifampicin and carbamazepine) can decrease its effectiveness. Timing of co-administration is crucial — take interacting drugs at least 6–12 hours apart from GIOTRIF.
GIOTRIF (afatinib) is a substrate and inhibitor of the drug transporter P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Unlike many other cancer drugs, afatinib is not significantly metabolised by cytochrome P450 (CYP) enzymes, which means its drug interactions are primarily related to P-gp transport rather than hepatic metabolism. However, several classes of medications can significantly affect GIOTRIF blood levels or have their own levels altered by GIOTRIF.
Drugs That Increase GIOTRIF Levels (P-gp Inhibitors)
The following medications can increase the blood concentration of GIOTRIF and thereby increase the risk and severity of side effects. They should be taken as far apart in time as possible from GIOTRIF — ideally 6 hours before or after (for drugs taken twice daily) or 12 hours before or after (for drugs taken once daily):
| Drug | Therapeutic Use | Management |
|---|---|---|
| Ritonavir | HIV treatment (protease inhibitor) | Stagger dosing by 6–12 hours |
| Ketoconazole | Antifungal (not as shampoo) | Stagger dosing by 6–12 hours |
| Itraconazole | Antifungal | Stagger dosing by 6–12 hours |
| Erythromycin | Antibiotic (macrolide) | Stagger dosing by 6–12 hours |
| Nelfinavir | HIV treatment (protease inhibitor) | Stagger dosing by 6–12 hours |
| Saquinavir | HIV treatment (protease inhibitor) | Stagger dosing by 6–12 hours |
| Verapamil | Heart disease (calcium channel blocker) | Stagger dosing by 6–12 hours |
| Quinidine | Heart rhythm disorders | Stagger dosing by 6–12 hours |
| Amiodarone | Heart rhythm disorders | Stagger dosing by 6–12 hours |
| Ciclosporin | Immunosuppressant | Stagger dosing by 6–12 hours |
| Tacrolimus | Immunosuppressant | Stagger dosing by 6–12 hours |
Drugs That Decrease GIOTRIF Effectiveness (P-gp Inducers)
The following medications may reduce the blood levels of GIOTRIF and potentially reduce its anti-cancer effectiveness:
| Drug | Therapeutic Use | Recommendation |
|---|---|---|
| Rifampicin | Antibiotic for tuberculosis | Avoid combination; inform your doctor |
| Carbamazepine | Anti-epileptic / seizure medication | Avoid combination; inform your doctor |
| Phenytoin | Anti-epileptic / seizure medication | Avoid combination; inform your doctor |
| Phenobarbital | Anti-epileptic / seizure medication | Avoid combination; inform your doctor |
| St John’s Wort | Herbal remedy for mild depression | Avoid combination; inform your doctor |
Drugs Whose Levels May Be Increased by GIOTRIF
GIOTRIF may increase the blood levels of certain other medicines by inhibiting P-gp and BCRP transporters. These include:
- Sulfasalazine – used to treat inflammatory bowel disease and rheumatoid arthritis. Blood levels may increase.
- Rosuvastatin – a statin used to lower cholesterol. Blood levels may increase, potentially raising the risk of muscle-related side effects.
Always inform your doctor or pharmacist about all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements, before starting GIOTRIF.
What Is the Correct Dosage of GIOTRIF?
Quick Answer: The recommended starting dose of GIOTRIF is 40 mg once daily, taken on an empty stomach. Your doctor may adjust the dose up or down (between 20 mg and 50 mg) depending on how well you tolerate the treatment. Always take it at least 1 hour before or 3 hours after food.
Adults
The recommended dose of GIOTRIF for adults is 40 mg taken orally once daily. Your oncologist will determine the most appropriate dose based on your individual circumstances, including body weight, kidney function, and tolerability. If side effects are significant, the dose may be reduced in 10 mg decrements (to 30 mg or 20 mg once daily). Conversely, if the drug is well tolerated and there are no significant side effects after 21 days of treatment, the dose may be increased to a maximum of 50 mg daily.
| Dose | Indication | Notes |
|---|---|---|
| 40 mg once daily | Standard starting dose | For EGFR mutation-positive NSCLC and squamous NSCLC |
| 50 mg once daily | Dose escalation | Only if well tolerated for at least 21 days (maximum dose) |
| 30 mg once daily | First dose reduction | For moderate side effects |
| 20 mg once daily | Second dose reduction | Minimum effective dose |
How to Take GIOTRIF
Correct administration of GIOTRIF is essential for optimal absorption and effectiveness:
- Take without food: Take GIOTRIF at least 1 hour before eating, or wait at least 3 hours after a meal.
- Once daily at the same time: Taking the tablet at a consistent time each day helps maintain steady blood levels and makes it easier to remember.
- Swallow whole: Do not split, crush, or chew the tablet. Swallow it with a glass of still (non-carbonated) water.
- If you cannot swallow: You may dissolve the tablet in approximately 100 ml of still water (do not use any other liquid). Drop the tablet into the water without crushing it, and stir occasionally until it has dissolved into very small particles (this may take up to 15 minutes). Drink the solution immediately, then rinse the glass with water and drink the rinse to ensure you receive the full dose.
- Nasogastric tube: If you cannot swallow and have a feeding tube, your doctor may direct that GIOTRIF be administered through the tube.
Children and Adolescents
GIOTRIF is not recommended for use in children or adolescents under 18 years of age. There is no established safety or efficacy data in paediatric patients. Do not give this medicine to children.
Elderly Patients
No specific dose adjustments are required for elderly patients based on age alone. However, elderly patients may be more susceptible to certain side effects, particularly diarrhoea and skin reactions. Kidney function, which often declines with age, should be monitored, as reduced renal clearance can lead to higher drug exposure. Your doctor will assess your overall health and organ function when determining the appropriate dose.
Missed Dose
If you forget to take a dose of GIOTRIF:
- More than 8 hours until your next scheduled dose: Take the missed dose as soon as you remember.
- Less than 8 hours until your next scheduled dose: Skip the missed dose entirely. Take your next dose at the usual time.
- Never double up: Do not take two tablets at once to make up for a missed dose.
Overdose
If you take more GIOTRIF than prescribed, contact your doctor or pharmacist immediately. Symptoms of overdose may include increased severity of known side effects, particularly diarrhoea, skin rash, nausea, and vomiting. There is no specific antidote for afatinib overdose. Treatment is supportive and symptomatic. Your doctor may need to temporarily discontinue treatment.
What Are the Side Effects of GIOTRIF?
Quick Answer: The most common side effects of GIOTRIF are diarrhoea (very common, occurring in more than 90% of patients), skin rash, mouth sores, nail infections, decreased appetite, nosebleeds, nausea, and vomiting. Serious but less common side effects include interstitial lung disease, gastrointestinal perforation, and severe skin reactions. Early management of diarrhoea and skin rash is crucial.
Like all medicines, GIOTRIF can cause side effects, although not everybody gets them. Many of the side effects of GIOTRIF are related to its mechanism of action — blocking EGFR and other ErbB family receptors that are also present in normal tissues such as the skin, gastrointestinal tract, and lungs. Understanding what to expect and how to manage these effects is an important part of treatment.
The side effects are grouped below by frequency, based on clinical trial data and post-marketing surveillance:
Very Common
- Diarrhoea (can lead to dehydration if not managed)
- Skin rash (acne-like eruptions)
- Mouth sores and inflammation (stomatitis)
- Nail infection (paronychia)
- Decreased appetite
- Nosebleeds (epistaxis)
- Nausea
- Vomiting
- Itching (pruritus)
- Dry skin
Common
- Hand-foot syndrome (palmar-plantar erythrodysaesthesia): pain, redness, swelling, or peeling of skin on hands or feet
- Elevated liver enzymes (AST and ALT) in blood tests
- Cystitis (urinary bladder inflammation with burning urination and urgency)
- Abnormal taste sensation (dysgeusia)
- Stomach pain, heartburn, indigestion
- Lip inflammation (cheilitis)
- Weight loss
- Runny nose (rhinorrhoea)
- Muscle spasms
- Fever
- Nail problems
- Dehydration (from prolonged diarrhoea)
- Low potassium levels in the blood (hypokalaemia)
- Impaired kidney function
- Eye irritation, conjunctivitis, dry eyes
Uncommon
- Interstitial lung disease (ILD): inflammation of the lung tissue, potentially life-threatening
- Pancreatitis (inflammation of the pancreas)
- Gastrointestinal perforation (hole in the stomach or bowel wall)
- Keratitis (inflammation of the cornea)
- Abnormal eyelash growth (including misdirected growth that may damage the eye surface)
Rare
- Stevens-Johnson syndrome (severe blistering of the skin)
- Toxic epidermal necrolysis (severe peeling of the skin)
Managing Diarrhoea
Diarrhoea is the most common and potentially most serious side effect of GIOTRIF. It occurs in the vast majority of patients, often starting within the first few weeks of treatment. Proactive management is essential:
- Have anti-diarrhoeal medication (e.g. loperamide) available before you start GIOTRIF.
- Begin anti-diarrhoeal treatment at the first sign of diarrhoea — do not wait for it to worsen.
- Drink plenty of fluids to prevent dehydration.
- Contact your doctor promptly if diarrhoea lasts more than 2 days or becomes severe.
- Severe or prolonged diarrhoea may require dose reduction, treatment interruption, or discontinuation.
Managing Skin Reactions
Skin rash (typically acne-like) is very common with GIOTRIF and other EGFR-targeting therapies. Sun-exposed areas may be more affected. Management includes:
- Use sunscreen and protective clothing, even on cloudy days.
- Moisturise the skin regularly with fragrance-free emollients.
- Report rash early to your doctor — early treatment leads to better outcomes.
- If the rash becomes severe (e.g. blistering or widespread peeling), contact your doctor immediately, as treatment may need to be stopped.
How Should You Store GIOTRIF?
Quick Answer: Store GIOTRIF in its original packaging, away from moisture and light. Keep it out of the reach and sight of children. Do not use after the expiry date printed on the carton and blister pack.
Proper storage of GIOTRIF is important to maintain the effectiveness and safety of the medication. Follow these guidelines:
- Keep out of reach of children: Store the medication where children cannot see or access it.
- Check the expiry date: Do not use GIOTRIF after the expiry date (marked "EXP") on the carton, protective pouch, and blister pack. The expiry date refers to the last day of the stated month.
- Store in original packaging: Keep the tablets in their original blister packs inside the protective aluminium pouch. The packaging is designed to protect against moisture and light.
- Moisture-sensitive: Each aluminium pouch contains a desiccant sachet to absorb moisture — do not swallow the desiccant.
- Light-sensitive: Protect the tablets from direct light exposure.
- Disposal: Do not dispose of medicines via household waste or wastewater. Ask your pharmacist how to safely dispose of medicines you no longer use. This helps protect the environment.
GIOTRIF 20 mg film-coated tablets are white to yellowish, round tablets debossed with the code "T20" on one side and the Boehringer Ingelheim company symbol on the other. They are available in perforated unit-dose blisters containing 7 tablets each, packaged within protective aluminium pouches. Packs contain 1, 2, or 4 blisters (7, 14, or 28 tablets). Not all pack sizes may be marketed in every country.
What Does GIOTRIF Contain?
Quick Answer: Each GIOTRIF 20 mg tablet contains 20 mg of afatinib (as dimaleate) as the active ingredient, along with inactive excipients including lactose monohydrate. The film coating contains hypromellose, macrogol 400, titanium dioxide, talc, and polysorbat 80.
Active Ingredient
The active substance is afatinib. Each film-coated tablet contains 20 mg of afatinib (present in the form of afatinib dimaleate). Afatinib dimaleate is the salt form used in the pharmaceutical formulation to ensure adequate stability and bioavailability of the active compound.
Inactive Ingredients (Excipients)
The tablet core contains the following excipients:
- Lactose monohydrate – a sugar-based filler. Patients with known lactose intolerance should consult their doctor before taking GIOTRIF.
- Microcrystalline cellulose (E460) – a plant-derived filler and binder.
- Colloidal anhydrous silica (E551) – a flow agent.
- Crospovidone type A – a disintegrant that helps the tablet break down in the stomach.
- Magnesium stearate (E470b) – a lubricant used in tablet manufacturing.
The film coating contains:
- Hypromellose (E464) – forms the film coating.
- Macrogol 400 – a plasticiser for the film coating.
- Titanium dioxide (E171) – a white colourant.
- Talc (E553b) – an anti-adherent.
- Polysorbat 80 (E433) – an emulsifier.
Marketing Authorisation Holder
GIOTRIF is manufactured and marketed by Boehringer Ingelheim International GmbH, based in Ingelheim am Rhein, Germany. Additional manufacturing sites include Boehringer Ingelheim Pharma GmbH & Co. KG (Germany) and Boehringer Ingelheim France (Paris, France). The medicine is authorised throughout the European Union and in numerous other countries worldwide.
Frequently Asked Questions About GIOTRIF
GIOTRIF (afatinib) is a targeted cancer therapy used to treat non-small cell lung cancer (NSCLC). It is approved for first-line treatment of EGFR mutation-positive NSCLC, where the tumour has been identified through molecular testing as having activating EGFR mutations (such as exon 19 deletions or exon 21 L858R mutations). It is also used for squamous NSCLC that has progressed after platinum-based chemotherapy. GIOTRIF works by irreversibly blocking the ErbB family of receptors, which drive cancer cell growth.
The most common side effects of GIOTRIF include diarrhoea (occurring in more than 90% of patients), skin rash (acne-like eruptions), mouth sores (stomatitis), nail infections (paronychia), decreased appetite, nosebleeds, nausea, and vomiting. Diarrhoea and skin rash are the most frequent reasons for dose adjustment. It is essential to have anti-diarrhoeal medication available before starting treatment and to begin it at the first sign of diarrhoea. Most side effects can be managed effectively with supportive care and, when necessary, dose modifications.
Take GIOTRIF once daily on an empty stomach — at least 1 hour before eating or 3 hours after a meal. Swallow the tablet whole with a glass of still (non-carbonated) water. Do not crush, chew, or split the tablet. Take it at approximately the same time each day. If you cannot swallow the tablet, you may dissolve it in about 100 ml of still water (stirring occasionally for up to 15 minutes) and drink immediately, then rinse the glass and drink the rinse.
Some medications can significantly affect GIOTRIF blood levels. P-glycoprotein (P-gp) inhibitors such as ritonavir, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, amiodarone, ciclosporin, and tacrolimus can increase afatinib levels — these should be taken as far apart as possible (6–12 hours) from GIOTRIF. P-gp inducers like rifampicin, carbamazepine, phenytoin, and St John’s Wort may reduce its effectiveness. GIOTRIF may also increase levels of sulfasalazine and rosuvastatin. Always inform your doctor about all medications and supplements you take.
GIOTRIF should not be used during pregnancy unless clearly necessary, as it may harm the unborn baby. Women of childbearing potential should use effective contraception during treatment and for at least 1 month after the last dose. If you become pregnant while taking GIOTRIF, contact your doctor immediately. Breastfeeding is not recommended during treatment, as the risk to the nursing infant cannot be excluded. Discuss family planning with your oncologist before, during, and after treatment.
Severe diarrhoea is one of the most important side effects to manage proactively. At the first sign of diarrhoea, drink plenty of fluids and immediately start anti-diarrhoeal medication such as loperamide. You should have this medication available before starting GIOTRIF. Contact your doctor promptly if diarrhoea persists for more than 2 days or becomes severe, as it can lead to dehydration, electrolyte imbalances (particularly low potassium), and kidney problems. Your doctor may reduce your dose or temporarily pause treatment until the diarrhoea resolves.
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- European Medicines Agency (EMA). GIOTRIF (afatinib) – Summary of Product Characteristics. European Public Assessment Report (EPAR). Last updated 2024. Available at: ema.europa.eu/en/medicines/human/EPAR/giotrif
- Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334. doi:10.1200/JCO.2012.44.2806
- Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6). Lancet Oncol. 2014;15(2):213-222. doi:10.1016/S1470-2045(13)70604-1
- Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8). Lancet Oncol. 2015;16(8):897-907. doi:10.1016/S1470-2045(15)00006-6
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025. Available at: nccn.org
- European Society for Medical Oncology (ESMO). Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(1):12-35. doi:10.1016/j.annonc.2023.10.015
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Available at: who.int
- Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-8
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in oncology, pulmonary medicine, and clinical pharmacology. Our team follows the GRADE evidence framework and adheres to international clinical practice guidelines from ESMO, NCCN, and the WHO.
Content authored by medical professionals with expertise in oncology, pharmacology, and evidence-based medicine. All claims are referenced to peer-reviewed literature.
Independently reviewed by the iMedic Medical Review Board. All content is verified against current EMA assessment reports, ESMO and NCCN guidelines, and published clinical trial data.
Editorial Standards: iMedic maintains strict independence with no pharmaceutical company sponsorship or advertising. Our content is based on Level 1A evidence (systematic reviews and randomised controlled trials) wherever available. Read more about our editorial standards and medical team.